New progress in the adjustment of the medical insurance catalogue in 2022: more than 300 drugs passed the preliminary form review

【Pharmaceutical Network Industry Dynamics】 On September 6, the National Medical Security Bureau announced the list of drugs that passed the preliminary form review in 2022 for the adjustment of the national basic medical insurance, work injury insurance and maternity insurance drug list
.

The list shows that 344 drugs passed the preliminary formal examination
.

It is reported that on September 6, the National Medical Insurance Bureau issued an announcement
on the announcement of drugs and related information that have passed the preliminary form review of the adjustment of the national basic medical insurance, work injury insurance and maternity insurance drug catalogue in 2022.

According to the 2022 National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalogue (hereinafter referred to as the National Medical Insurance Drug Catalogue) to adjust the work arrangement, the State Medical Insurance Bureau recently conducted a preliminary formal review of the declared drugs, and publicized
the drugs and information that passed the review.

According to the interpretation released on the same day, from 9:00 on July 1, 2022 to 17:00 on July 14, 2022, the national medical insurance information platform received a
total of 537 enterprise declarations, involving 490 drugs (generic names, the same below).

After review, 344 drugs passed the preliminary form examination, and the proportion of passing was 70%.
It is reported that compared with 2021 (474 drugs and 271 passes), the number of drugs declared and passed the preliminary form examination has increased
to a certain extent.

In terms of pass rate, the proportion of drugs outside the list is 60%, and the proportion of drugs in the list is 91%.
The industry said that the preliminary form review is a preliminary review of whether the declared drugs meet the declaration conditions for the adjustment of the national medical insurance drug list in that year and the integrity of drug information
.

The preliminary formal review of the drug declaration materials can ensure that the declared drugs meet the declaration conditions on the one hand, and on the other hand, the completeness and standardization of the declaration materials are reviewed, and the authenticity of some information is verified to the relevant parties according to the needs of the work, which is conducive to ensuring that the information provided to the experts is more accurate and complete
.

At the same time, in order to actively accept social supervision, to ensure that the results of the formal examination are accurate
.

The drug passes the formal examination, indicating that the drug is eligible for the next step of expert review
.

It is understood that this year, some of the more expensive drugs have passed the preliminary form examination
.

However, the National Medical Insurance Bureau said that this only means that the drug meets the declaration conditions and is eligible to
enter the next stage.

Whether such drugs can eventually enter the national medical insurance drug list also needs to be strictly evaluated in many ways, including economy, and the exclusive drugs that pass the review must be negotiated, and the non-exclusive drugs must be bid, and only after negotiation or bidding can they be included in the list
.

The National Medical Insurance Bureau also said that it will further verify the relevant information based on the feedback received during the publicity period, determine the scope of drugs that will eventually pass the formal examination, and announce
it to the public.

Subsequently, follow-up work
such as expert review, negotiation and bidding will be promoted as planned.

According to statistics, since the establishment of the National Medical Insurance Bureau in 2018, the medical insurance drug catalogue has cumulatively included 507 new drugs and good drugs, transferred 391 drugs with inaccurate efficacy, and the current version of the medical insurance catalogue has increased to 2860 western medicines and proprietary Chinese medicines
.

Among them, 250 drugs have been included in medical insurance through price negotiations, and many "sky-high drugs" have negotiated "civilian prices", and most drugs have obtained low prices, with an average price reduction of more than 50%.


It is understood that today, the shortcomings of oncology drugs, chronic diseases, rare diseases and children's drugs have been gradually filled, the structure and efficacy level of drugs in the medical insurance catalogue have been greatly optimized, and the drug guarantee in most treatment areas has been synchronized with the international community, and the guarantee capacity has been significantly improved
.

Disclaimer: In no event shall the information or opinions expressed herein constitute investment advice
to any person.